|
COPYRIGHT 2001 PR Newswire Association LLC
SOUTH SAN FRANCISCO, Calif., and Albany, N.Y., May 31 /PRNewswire/ --
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) and Albany Molecular Research, Inc. (Nasdaq: AMRI) today announced that they have entered into an agreement for medicinal chemistry services to support and accelerate Rigel's product development program in the area of IgE receptor regulation on mast cells for asthma and allergy. Rigel intends to begin clinical trials in this program in 2002.
Under the terms of the agreement, Albany Molecular will provide Rigel with expertise to accelerate the optimization of compounds in Rigel's mast cell program. The goal of the mast cell program is to identify and develop small molecule compounds that inhibit the secretion of multiple inflammatory factors,...
Read the full article for free courtesy of your local library.
|
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
